Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immune 1(TM) complexed PSA assay

W. J. Allard, C. D. Cheli, D. L. Morris, J. Goldblatt, Y. Pierre, L. Kish, Y. Chen, J. Dai, R. L. Lvessella, D. W. Chan, M. K. Schwartz, Z. Zhou, K. K. Yeung

Research output: Contribution to journalArticlepeer-review

Abstract

We conducted a multicenter evaluation of the analytical and clinical performance of the automated Bayer Immuno 1(TM) complexed PSA (cPSA) assay, and compared assay performance to the Bayer Immuno 1(TM) PSA assay. We sought to determine whether measurements of cPSA could be of clinical utility in the management of patients with prostate cancer. Results of the 10-day imprecision across three evaluation sites produced total CV < 2.50% and an analytical sensitivity of 0.02 μg/L. There was an increased trend in clinical sensitivity for prostate cancer with increasing stage of disease (71-86%). Clinical specificity for patients with benign urogenital disease was 74.8%, and for other nonprostate diseases ranged from 91.1-100%. Retrospective serial monitoring of 155 patients with prostate cancer demonstrated concordance of cPSA measurements to clinical status for 97% of the patients analyzed. Results from the clinical studies using the Bayer Immuno 1 cPSA assay were comparable to results obtained with the Bayer Immuno 1 PSA assay. The Bayer Immuno 1 cPSA assay demonstrates analytical performance and clinical effectiveness in the management of prostate cancer patients during the course of disease and therapy.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
JournalInternational Journal of Biological Markers
Volume14
Issue number2
StatePublished - Jul 17 1999
Externally publishedYes

Keywords

  • Automation
  • Immunoassays
  • PSA-ACT
  • Performance
  • Prostate cancer
  • Prostate specific antigen
  • Tumor markers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Clinical Biochemistry
  • Cancer Research

Fingerprint Dive into the research topics of 'Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immune 1(TM) complexed PSA assay'. Together they form a unique fingerprint.

Cite this